MX394541B - Dihidrotestosterona y derivados y promotores de dihidrotestosterona en el tratamiento del cancer - Google Patents
Dihidrotestosterona y derivados y promotores de dihidrotestosterona en el tratamiento del cancerInfo
- Publication number
- MX394541B MX394541B MX2018014049A MX2018014049A MX394541B MX 394541 B MX394541 B MX 394541B MX 2018014049 A MX2018014049 A MX 2018014049A MX 2018014049 A MX2018014049 A MX 2018014049A MX 394541 B MX394541 B MX 394541B
- Authority
- MX
- Mexico
- Prior art keywords
- dihydrotestosterone
- treatment
- cancer
- promoters
- derivatives
- Prior art date
Links
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 title abstract 5
- 229960003473 androstanolone Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338122P | 2016-05-18 | 2016-05-18 | |
| PCT/US2017/033213 WO2017201217A1 (en) | 2016-05-18 | 2017-05-18 | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014049A MX2018014049A (es) | 2019-04-01 |
| MX394541B true MX394541B (es) | 2025-03-24 |
Family
ID=58794186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014049A MX394541B (es) | 2016-05-18 | 2017-05-18 | Dihidrotestosterona y derivados y promotores de dihidrotestosterona en el tratamiento del cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170333451A1 (https=) |
| EP (1) | EP3458071A1 (https=) |
| JP (2) | JP2019516709A (https=) |
| KR (1) | KR102466886B1 (https=) |
| CN (1) | CN109562116A (https=) |
| AU (1) | AU2017268351A1 (https=) |
| BR (1) | BR112018073627A2 (https=) |
| CA (1) | CA3024501A1 (https=) |
| EA (1) | EA201892631A1 (https=) |
| IL (1) | IL262863A (https=) |
| MX (1) | MX394541B (https=) |
| PH (1) | PH12018502381A1 (https=) |
| WO (1) | WO2017201217A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11289213B2 (en) | 2017-08-31 | 2022-03-29 | Westinghouse Electric Company Llc | Control rods for light water reactors |
| US11464658B2 (en) * | 2018-10-25 | 2022-10-11 | Medtronic Vascular, Inc. | Implantable medical device with cavitation features |
| PH12021552866A1 (en) * | 2019-05-14 | 2022-11-07 | Tyme Inc | Compositions and methods for treating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| US20240016815A1 (en) * | 2020-12-02 | 2024-01-18 | Hoffman Technologies Llc | Compositions and methods for modulating cancer in non-human mammals |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098403A1 (en) * | 2001-06-01 | 2002-12-12 | Georgetown University | Steroid hormone and non-steroidal anti-inflammatory drug combinations for inducing tumor cell apoptosis |
| JP5449775B2 (ja) * | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
| PL2804599T3 (pl) * | 2012-01-17 | 2019-06-28 | Tyme, Inc. | Terapia skojarzona do leczenia nowotworu złośliwego |
| US8481498B1 (en) * | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-05-18 MX MX2018014049A patent/MX394541B/es unknown
- 2017-05-18 BR BR112018073627-9A patent/BR112018073627A2/pt not_active IP Right Cessation
- 2017-05-18 EP EP17726439.7A patent/EP3458071A1/en not_active Withdrawn
- 2017-05-18 CN CN201780030526.6A patent/CN109562116A/zh active Pending
- 2017-05-18 JP JP2018560496A patent/JP2019516709A/ja active Pending
- 2017-05-18 EA EA201892631A patent/EA201892631A1/ru unknown
- 2017-05-18 US US15/598,818 patent/US20170333451A1/en not_active Abandoned
- 2017-05-18 KR KR1020187036194A patent/KR102466886B1/ko active Active
- 2017-05-18 CA CA3024501A patent/CA3024501A1/en active Pending
- 2017-05-18 AU AU2017268351A patent/AU2017268351A1/en not_active Abandoned
- 2017-05-18 WO PCT/US2017/033213 patent/WO2017201217A1/en not_active Ceased
-
2018
- 2018-03-09 US US15/917,106 patent/US20180193360A1/en not_active Abandoned
- 2018-11-07 IL IL262863A patent/IL262863A/en unknown
- 2018-11-12 PH PH12018502381A patent/PH12018502381A1/en unknown
-
2020
- 2020-03-19 US US16/823,411 patent/US20200215082A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022178011A patent/JP2023011881A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014049A (es) | 2019-04-01 |
| JP2019516709A (ja) | 2019-06-20 |
| IL262863A (en) | 2018-12-31 |
| EA201892631A1 (ru) | 2019-04-30 |
| US20200215082A1 (en) | 2020-07-09 |
| EP3458071A1 (en) | 2019-03-27 |
| AU2017268351A1 (en) | 2018-12-06 |
| US20170333451A1 (en) | 2017-11-23 |
| PH12018502381A1 (en) | 2019-03-11 |
| JP2023011881A (ja) | 2023-01-24 |
| BR112018073627A2 (pt) | 2019-02-26 |
| WO2017201217A1 (en) | 2017-11-23 |
| CA3024501A1 (en) | 2017-11-23 |
| CN109562116A (zh) | 2019-04-02 |
| KR102466886B1 (ko) | 2022-11-14 |
| KR20190008557A (ko) | 2019-01-24 |
| US20180193360A1 (en) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202110554B (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
| MX2017015896A (es) | Agente anticancerigeno. | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| PH12018502381A1 (en) | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2017005929A (es) | Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit. | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| WO2014194312A3 (en) | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| PH12019500725A1 (en) | Methods of treating acute kidney injury | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| MX382778B (es) | Metodos para tratar cancer pancreatico | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2016009663A (es) | Derivados de icariina. | |
| EP4640237A3 (en) | Macrophage-based therapy for use in the treatment of acute liver injury | |
| TW201613587A (en) | Medical treatments based on anamorelin |